TITLE

The Association Between Dietary Sodium Intake, ESRD, and All-Cause Mortality in Patients With Type 1 Diabetes

AUTHOR(S)
THOMAS, MERLIN C.; MORAN, JOHN; FORSBLOM, CAROL; HARJUTSALO, VALMA; THORN, LENA; AHOLA, AILA; WADÉN, JOHAN; TOLONEN, NINA; SARAHEIMO, MARKKU; GORDIN, DANIEL; GROOP, PER-HENRIK
PUB. DATE
April 2011
SOURCE
Diabetes Care;Apr2011, Vol. 34 Issue 4, p861
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE--Many guidelines recommend reduced consumption of salt in patients with type 1 diabetes, but it is unclear whether dietary sodium intake is associated with mortality and end-stage renal disease (ESRD). RESEARCH DESIGN AND METHODS--In a nationwide multicenter study (the FinnDiane Study) between 1998 and 2002, 2,807 enrolled adults with type 1 diabetes without ESRD were prospectively followed. Baseline urinary sodium excretion was estimated on a 24-h urine collection. The predictors of all-cause mortality and ESRD were determined by Cox regression and competing risk modeling, respectively. RESULTS--The median follow-up for survival analyses was 10 years, during which 217 deaths were recorded (7.7%). Urinary sodium excretion was nonlinearly associated with all-cause mortality, such that individuals with the highest daily urinary sodium excretion, as well as the lowest excretion, had reduced survival. This association was independent age, sex, duration of diabetes, the presence and severity of chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR] and log albumin excretion rate), the presence of established cardiovascular disease, and systolic blood pressure. During follow-up, 126 patients developed ESRD (4.5%). Urinary sodium excretion was inversely associated with the cumulative incidence of ESRD, such that individuals with the lowest sodium excretion had the highest cumulative incidence of ESRD. CONCLUSIONS--In patients with type 1 diabetes, sodium was independently associated with all-cause mortality and ESRD. Although we have not demonstrated causality, these findings support the calls for caution before applying salt restriction universally. Clinical trials must be performed in diabetic patients to formally test the utility/risk of sodium restriction in this setting.
ACCESSION #
60705069

 

Related Articles

  • All-cause and cause-specific mortality associated with diabetes in prevalent hemodialysis patients. Sattar, Abdus; Argyropoulos, Christos; Weissfeld, Lisa; Younas, Nizar; Fried, Linda; Kellum, John A; Unruh, Mark // BMC Nephrology;2012, Vol. 13 Issue 1, p130 

    Background: Diabetes is the most common risk factor for end-stage renal disease (ESRD) and has been associated with increased risk of death. In order to better understand the influence of diabetes on outcomes in hemodialysis, we examine the risk of death of diabetic participants in the...

  • Integrating care: diabetes and kidney disease. Jenkins, Karen // Journal of Renal Nursing;2012, Vol. 4 Issue 5, p220 

    The author discusses the importance of integrating diabetes and kidney disease mainly owing to the fact that chronic kidney disease (CKD) and diabetes are strongly associated with an increased cardiovascular risk and that the management of patients with these comorbidities remains fragmented.

  • Diabetic kidney disease: collaboration is the key. Kumwenda, Mick // Journal of Renal Nursing;2012, Vol. 4 Issue 5, p221 

    The author highlights the issue of progression of diabetic kidney disease with hypertension, proteinuria and renal function decline; and calls for a collaborative approach in its treatment. He discusses a study by Glover and colleagues that reports the benefits on patient outcomes of local...

  • Mortality due to chronic kidney disease increasing worldwide.  // Pulse International;10/31/2016, Vol. 17 Issue 20, p12 

    The article reports on the rising number of global deaths due to chronic kidney disease (CKD), as confirmed by a Global Burden of Disease study published in the medical journal "The Lancet." The study indicates that CKD mortality increased by 32% between 2005 and 2015. The professional...

  • Molecular Mechanisms of Diabetic Nephropathy and Its Therapeutic Intervention. Sho-ichi Yamagishi; Fukami, Kei; Ueda, Seiji; Okuda, Seiya // Current Drug Targets;Aug2007, Vol. 8 Issue 8, p952 

    Diabetic nephropathy is a leading cause of end-stage renal failure, which could account for disabilities and high mortality rates in patients with diabetes. Diabetic nephropathy seems to occur as a result of an interaction between metabolic and hemodynamic factors, which activate common pathways...

  • Hypoglycemia, Chronic Kidney Disease, and Diabetes Mellitus. Alsahli, Mazen; Gerich, John E. // Mayo Clinic Proceedings;Nov2014, Vol. 89 Issue 11, p1566 

    Hypoglycemia is a major problem associated with substantial morbidity and mortality in patients with diabetes and is often a major barrier to achieving optimal glycemic control. Chronic kidney disease not only is an independent risk factor for hypoglycemia but also augments the risk of...

  • Mortality Associated with Chronic Kidney Disease, Diabetes and Anaemia: A Population Based Study. Mcelduff, Patrick; Middleton, Rachael J.; Gibson, John M.; O'Donoghue, Donal J.; New, John P. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA264 

    The article discusses a study which aims to determine mortality according to stage of chronic kidney disease (CKD) together with the confounding affects of diabetes and anemia conducted in Salford, England. Subjects were aged 20 years or older who had a serum creatinine performed between July 1,...

  • The effect of diabetes on incidence and mortality in end-stage renal disease in Germany. Hoffmann, Falk; Haastert, Burkhard; Koch, Michael; Giani, Guido; Glaeske, Gerd; Icks, Andrea // Nephrology Dialysis Transplantation;May2011, Vol. 26 Issue 5, p1634 

    Background. We aimed to examine the epidemiology and mortality risk of patients with incident end-stage renal disease (ESRD) in diabetic and non-diabetic individuals and to determine differences between sexes.Methods. We used the claims data of a statutory health insurance company. Patients aged...

  • Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Jorsal, Anders; Tarnow, Lise; Frystyk, Jan; Lajer, Maria; Flyvbjerg, Allan; Parving, Hans-Henrik; Vionnet, Nathalie; Rossing, Peter // Kidney International;Sep2008, Vol. 74 Issue 5, p649 

    Adiponectin levels are increased in patients with type I diabetes especially in the presence of microangiopathy. Here we determined the predictive value of serum adiponectin levels and 8 adiponectin gene polymorphisms for mortality, cardiovascular events and end-stage renal disease in type I...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics